SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
March 24, 2021
(Exact name of registrant as specified in its charter)
(State or other jurisdiction
|12701 Commonwealth Drive, ||Suite 9,||Fort Myers,||Florida||33913|
|(Address of principal executive offices)||(Zip Code)|
(Registrant’s telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol||Name of each exchange on which registered|
|Common stock ($0.001 par value)||NEO||NASDAQ|
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
|Item 7.01||Regulation FD Disclosure.|
On March 24, 2021, NeoGenomics, Inc. (“NeoGenomics”, the “Company”), announced it had agreed, through its wholly-owned subsidiary NeoGenomics Bioinformatics, Inc. to acquire Intervention Insights, Inc. d/b/a Trapelo Health (“Trapelo”), an Information Technology company focused on precision oncology. The agreement purchase price is $65 million, and consists of $35 million in cash on hand and $30 million in the Company's common stock. The acquisition is subject to satisfaction of certain customary closing conditions and is expected to close in April 2021.
On March 24, 2021, the Company issued a press release announcing the acquisition of Trapelo.
A copy of the press release is furnished herewith as Exhibit 99.1 to the Current Report on Form 8-K.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|By:||/s/ Kathryn B. McKenzie|
|Kathryn B. McKenzie|
|Chief Financial Officer|
|March 24, 2021|